“The binding … for repaglinide at Sudlow site I increased by 1.3- … 1.7-fold with the Go-modified HSA and decreased slightly (i.e., up to 19 %) for the MGo-modified HSA, while nateglinide … only a small or insignificant change in binding with the same modified HSA samples.”
“These results indicated that binding by repaglinide and nateglinide with HSA can be altered significantly by modification of this protein with Go or MGo, making these modifications of potential interest in the treatment of patients with these drugs during diabetes.”